Evidence map›Paper›PMID 25234510›Full record

ArticleBMJ open2014

Long-term use and cost-effectiveness of secondary prevention drugs for heart disease in Western Australian seniors (WAMACH): a study protocol.

Anthony S Gunnell, Matthew W Knuiman, Elizabeth Geelhoed, Michael S T Hobbs, Judith M Katzenellenbogen, Joseph Hung, Jamie M Rankin, Lee Nedkoff, Thomas G Briffa, Michael Ortiz and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Anthony S GunnellSchool of Population Health, The University of Western Australia, Crawley, Western Australia, Australia.ORCID http://orcid.org/0000-0002-5432-6685
Matthew W KnuimanSchool of Population Health, The University of Western Australia, Crawley, Western Australia, Australia.
Elizabeth GeelhoedSchool of Population Health, The University of Western Australia, Crawley, Western Australia, Australia.
Michael S T HobbsSchool of Population Health, The University of Western Australia, Crawley, Western Australia, Australia.
Judith M KatzenellenbogenWestern Australian Centre for Rural Health, The University of Western Australia, Crawley, Western Australia, Australia.
Joseph HungSchool of Medicine & Pharmacology, Sir Charles Gairdner Hospital Unit, The University of Western Australia, Nedlands, Western Australia, Australia.
Jamie M RankinDepartment of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia.
Lee NedkoffSchool of Population Health, The University of Western Australia, Crawley, Western Australia, Australia.
Thomas G BriffaSchool of Population Health, The University of Western Australia, Crawley, Western Australia, Australia.
Michael OrtizSt Vincent's Clinical School, University of New South Wales, Darlinghurst, New South Wales, Australia.
Malcolm GilliesMedicineInsight, NPS MedicineWise, Sydney, New South Wales, Australia.
Anne CordingleyConsumer and Community Advisory Council, School of Population Health, The University of Western Australia, Crawley, Western Australia, Australia.
Mitch MesserHealth Consumers' Council (WA) Inc., Perth, Western Australia, Australia.
Christian GardnerSchool of Population Health, The University of Western Australia, Crawley, Western Australia, Australia.
Derrick LopezWestern Australian Centre for Rural Health, The University of Western Australia, Crawley, Western Australia, Australia.
Emily AtkinsSchool of Population Health, The University of Western Australia, Crawley, Western Australia, Australia.
Qun MaiClinical Modelling Unit, Western Australian Department of Health, Perth, Western Australia, Australia.
Frank M SanfilippoSchool of Population Health, The University of Western Australia, Crawley, Western Australia, Australia.ORCID http://orcid.org/0000-0003-3639-0787

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSecondary prevention drugs for cardiac disease have been demonstrated by clinical trials to be effective in reducing future cardiovascular and mortality events (WAMACH is the Western Australian Medication Adherence and Costs in Heart disease study). Hence, most countries have adopted health policies and guidelines for the use of these drugs, and included them in government subsidised drug lists to encourage their use. However, suboptimal prescribing and non-adherence to these drugs remains a universal problem. Our study will investigate trends in dispensing patterns of drugs for secondary prevention of cardiovascular events and will also identify factors influencing these patterns. It will also assess the clinical and economic consequences of non-adherence and the cost-effectiveness of using these drugs. METHODS AND ANALYSIS: This population-based cohort study will use longitudinal data on almost 40,000 people aged 65 years or older who were hospitalised in Western Australia between 2003 and 2008 for coronary heart disease, heart failure or atrial fibrillation. Linking of several State and Federal government administrative data sets will provide person-based information on drugs dispensed precardiac and postcardiac event, reasons for hospital admission, emergency department visits, mortality and medical visits. Dispensed drug trends will be described, drug adherence measured and their association with future all-cause/cardiovascular events will be estimated. The cost-effectiveness of these long-term therapies for cardiac disease and the impact of adherence will be evaluated. ETHICS AND DISSEMINATION: Human Research Ethics Committee (HREC) approvals have been obtained from the Department of Health (Western Australian #2011/62 and Federal) and the University of Western Australia (RA/4/1/1130), in addition to HREC approvals from all participating hospitals. Findings will be published in peer-reviewed medical journals and presented at local, national and international conferences. Results will also be disseminated to consumer groups.

Indexed as

AgedAtrial FibrillationCardiotonic AgentsClinical ProtocolsCohort StudiesCoronary DiseaseCost-Benefit AnalysisHeart DiseasesHeart FailureHumansLong-Term CareMedication AdherenceSecondary PreventionTreatment OutcomeWestern AustraliaCardiotonic AgentsCARDIOLOGYCLINICAL PHARMACOLOGYHEALTH ECONOMICS

Identifiers

PMID25234510
PMCPMC4170208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.